piR-hsa-211106 Inhibits the Progression of Lung Adenocarcinoma Through Pyruvate Carboxylase and Enhances Chemotherapy Sensitivity
| Autor: | Xinjia He, Li Meng, Wang Zibo, Anjing Gong, Yanhan Dong, Yuqiao Fan, Shuai Wang, Jinning Gao, Wenhua Xu, Xiaodan Hao, Yongmei Liu |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
Cancer Research non-coding RNA piRNA pyruvate carboxylase 03 medical and health sciences 0302 clinical medicine In vivo cancer drug sensitivity RC254-282 Original Research Messenger RNA Cell growth Chemistry Neoplasms. Tumors. Oncology. Including cancer and carcinogens RNA Non-coding RNA lung adenocarcinoma Pyruvate carboxylase body regions 030104 developmental biology Oncology Apoptosis Cell culture 030220 oncology & carcinogenesis embryonic structures Cancer research |
| Zdroj: | Frontiers in Oncology Frontiers in Oncology, Vol 11 (2021) |
| ISSN: | 2234-943X |
| Popis: | Although the importance of PIWI-interacting RNAs (piRNAs) in cancer has recently been recognized, studies on the role and functional mechanism of piRNAs in lung adenocarcinoma (LUAD) development and progression are limited. In this study, we identified 10 differently expressed piRNAs in LUAD tissues compared to normal tissues, among which, piR-hsa-211106 expression levels were downregulated in LUAD tissues and cell lines. Furthermore, the effects of piR-hsa-211106 on the malignant phenotypes and chemosensitivity of LUAD cells were detected by gain- and loss-of-function analyses in vitro and in vivo, which showed that piR-hsa-211106 inhibited LUAD cell proliferation, tumor growth, and migration, but promoted apoptosis. Moreover, our finding indicated that piR-hsa-211106 is a potential therapeutic target that synergistically imparts anticancer effects with a chemotherapeutic agent for LUAD-cisplatin. Further mechanistic investigation indicated that piR-hsa-211106 could bind to pyruvate carboxylase (PC) by RNA pull down and RNA immunoprecipitation assays and inhibited PC mRNA and protein expression. Our study demonstrates that piR-hsa-211106 inhibits LUAD progression by hindering the expression and function of PC and enhances chemotherapy sensitivity, suggesting that piR-hsa-211106 is a novel diagnostic and therapeutic target for LUAD. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|